 |
29 Products |  |
56 Diseases | | 29 Products |
|
158 Trials |  |
7362 News |  |
| «12...345678910111213...9596» |
- || Euflexxa (hyaluronic acid) / Ferring
New P1 trial: Phase 1b Clinical Trial to Evaluate PEP and EUFLEXXA for Knee Osteoarthritis (KOA) (clinicaltrials.gov) - Jun 16, 2024
P1, N=24, Not yet recruiting, Sponsor: Rion Inc.
- | Hernicore (condoliase) / Seikagaku, Ferring
Journal: Changes in Intervertebral Disc Properties after Intradiscal Injection of Condoliase for Painful Lumbar Disc Herniation. (Pubmed Central) - Jun 16, 2024
Patients in the young group with pretreatment disc height >11 mm had the greatest reduction in disc height than the over 50s group. In conclusion, the clinical outcomes in the over 50s group were comparable to those in the young group after injection of condoliase, whereas young patients with higher disc were more susceptible to disc height reduction.
- || Hernicore (condoliase) / Seikagaku, Ferring
Biomarker, Clinical data, Journal: Immediate Effects, Detailed Clinical Outcomes, and Prognostic Factors of Chemonucleolysis Using Condoliase for Lumbar Disc Herniation. (Pubmed Central) - Jun 16, 2024
In conclusion, the clinical outcomes in the over 50s group were comparable to those in the young group after injection of condoliase, whereas young patients with higher disc were more susceptible to disc height reduction. The comparison of baseline leg pain NRS shows a difference in leg pain NRS in the I-group when compared on the day after treatment (6.02
- | bicalutamide / Generic mfg.
Journal, Metastases: A Rare Case of Bicalutamide-Induced Severe Congestive Heart Failure in a Patient With Advanced Prostate Cancer. (Pubmed Central) - Jun 14, 2024
The recovery of LVEF and the absence of other etiologies reinforce the likelihood of bicalutamide-induced cardiotoxicity. This report underscores the importance of vigilant cardiovascular monitoring in patients receiving bicalutamide, prompt identification of cardiac dysfunction and possible mechanisms of bicalutamide cardiotoxicity, and the potential for cardiac recovery upon drug discontinuation and initiation of GDMT.
- | purified human menopausal gonadotropin / Generic mfg.
Journal: Quality evaluation of highly purified human menopausal gonadotropin preparations by means of gel electrophoresis and mass spectrometry. (Pubmed Central) - Jun 14, 2024
MS analysis proved to be a powerful tool for the identification and detailed characterization of the gonadotropins and the relevant peptides were identified with high sequence coverages. The results of this study are not only useful for the quality assessment of this class of complex biopharmaceuticals but may also serve as a supporting platform for further development of biopharmaceuticals based on modulation of the glycosylation pattern to enhance efficacy or reduce side effects.
- || Hernicore (condoliase) / Seikagaku, Ferring
Clinical data, Journal: Reply to "Letter to the Editor Concerning 'Clinical Outcomes of Condoliase Injection Therapy for Lateral Lumbar Disc Herniation' by Kagami et al.". (Pubmed Central) - Jun 13, 2024
The results of this study are not only useful for the quality assessment of this class of complex biopharmaceuticals but may also serve as a supporting platform for further development of biopharmaceuticals based on modulation of the glycosylation pattern to enhance efficacy or reduce side effects. No abstract available
- || Hernicore (condoliase) / Seikagaku, Ferring
Clinical data, Journal: Letter to the Editor Concerning "Clinical Outcomes of Condoliase Injection Therapy for Lateral Lumbar Disc Herniation" by Kagami et al. (Pubmed Central) - Jun 13, 2024
No abstract available No abstract available
- || Retrospective data, Review, Journal: Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease. (Pubmed Central) - Jun 12, 2024
Upadacitinib and risankizumab induced the highest clinical responses in bio-exposed patients. However, infliximab was not investigated in this population.
- ||| Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
P3 data, Clinical Trial,Phase III, Journal: Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial. (Pubmed Central) - Jun 11, 2024
P3
Only 5 patients (4 with CIS and 1 with Ta/T1) experienced clinical progression to muscle-invasive disease. At 60 months, Nadofaragene firadenovec-vncg allowed bladder preservation in nearly half of the patients and proved to be a safe option for BCG-unresponsive NMIBC.
- | Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Trial completion date, Trial primary completion date: Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov) - Jun 10, 2024
P3, N=24, Recruiting, Sponsor: Ferring Pharmaceuticals
At 60 months, Nadofaragene firadenovec-vncg allowed bladder preservation in nearly half of the patients and proved to be a safe option for BCG-unresponsive NMIBC. Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2024 --> Oct 2025
- || Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: Generalized Pustular Psoriasis of Pregnancy Successfully Treated With Certolizumab Pegol: A Case Report and Literature Review. (Pubmed Central) - Jun 7, 2024
To date, there are only 11 reported cases of this severe skin condition treated with a TNFi. We also discuss the pathogenesis of GPPP and the rationale behind using TNFi for its treatment.
- |||| Nubeqa (darolutamide) / Bayer, Orion Corp
New P2 trial: A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERMEDIATE UNFAVORABLE RISK PROSTATE CANCER DAROLUTAMIDE (ODM-201) CONCOMITANT A LA RADIOTHERAPIE CHEZ LES PATIENTS PRESENTANT UN CANCER DE LA PROSTATE A RISQUE INTERMEDIAIRE DEFAVORABLE : UNE ETUDE MULTICENTRIQUE RANDOMISEE NON-COMPARATIVE DE PHASE II (EUDRACT) - Jun 6, 2024
P2, N=62, Ongoing, Sponsor: Institut Bergoni
- | Enrollment open: Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (clinicaltrials.gov) - Jun 4, 2024
P2, N=120, Recruiting, Sponsor: Mayo Clinic
We also discuss the pathogenesis of GPPP and the rationale behind using TNFi for its treatment. Not yet recruiting --> Recruiting
- || Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective. (Pubmed Central) - Jun 3, 2024
(TNF-?) inhibitors, adalimumab, infliximab, and etanercept, are well studied in this patient population, and in some cases, HS was unresponsive to them...Also, golimumab showed promise in treating recalcitrant HS after the failure of other treatments, such as adalimumab and anti-interleukin-1. CPZ and golimumab can be efficacious treatment options for moderate-to-severe HS, especially in patients who are unresponsive to other TNF inhibitors, such as adalimumab.
- | Firmagon (degarelix) / Astellas, Ferring, bicalutamide / Generic mfg.
Journal: Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. (Pubmed Central) - Jun 1, 2024
P3
Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population.
- | Firmagon (degarelix) / Astellas, Ferring, bicalutamide / Generic mfg.
Journal: Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. (Pubmed Central) - Jun 1, 2024
P3
Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative radiotherapy. For individuals who can accept the additional duration of adverse effects, long-course ADT should be offered with postoperative radiotherapy.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Review, Journal: SARS-CoV-2 infection in pregnant patients on TNF? inhibitor: Real-life data with a review of literature. (Pubmed Central) - Jun 1, 2024
We reviewed 85 patients who received TNF?i (certolizumab pegol) during Mainland China's first wave of COVID-19 pandemic, from 21st Nov 2022-11?th Jan 2023...However, TNF?i users showed more prominent symptoms and longer recovery time. The pregnancy outcomes with TNF?i in such high-risk group for pregnancy loss was satisfactory.
- || Cervidil (dinoprostone) / Ferring
Clinical, Retrospective data, Journal: Comparing labour induction outcomes using misoprostol and dinoprostone in term pregnancies: A retrospective study at Kiambu Level 5 Hospital between 2018 and 2020. (Pubmed Central) - May 31, 2024
The use of dinoprostone, however, was linked to an increased risk of uterine rupture, possibly attributed to reduced labour monitoring given that staff held the belief that it is inherently safer than misoprostol. Consequently, even though the changeover was warranted, further investigation is needed to determine the reasons behind the rise in maternal mortalities, even though the MPDSR framework appeared to have been put in place to quell such an increase.
- ||||||| Rekovelle (follitropin delta) / Ferring
Trial completion: ADAPT-1: A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation (clinicaltrials.gov) - May 31, 2024
P3, N=302, Completed, Sponsor: Ferring Pharmaceuticals
Consequently, even though the changeover was warranted, further investigation is needed to determine the reasons behind the rise in maternal mortalities, even though the MPDSR framework appeared to have been put in place to quell such an increase. Active, not recruiting --> Completed
- | Cervidil (dinoprostone) / Ferring
New P4 trial: Comparison Between Propess and Cook Double-balloon Catheter for Cervical Priming (clinicaltrials.gov) - May 31, 2024
P4, N=28, Not yet recruiting, Sponsor: The University of Hong Kong
- | Goofice (elobixibat) / Ipsen
New trial: Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen (clinicaltrials.gov) - May 30, 2024
P=N/A, N=360, Not yet recruiting, Sponsor: Rajavithi Hospital
- Actemra IV (tocilizumab) / Roche, JW Pharma
RATE OF THERAPEUTIC FAILURES PRESENTED AFTER SWITCHING FROM TOCILIZUMAB TO ANOTHER BIOLOGICALS IN PATIENTS WITH RHEUMATOID ARTHRITIS FACING A SITUATION OF SUPPLY SHORTAGE () - May 29, 2024 - Abstract #EULAR2024EULAR_4463;
The data from this study show that the most effective molecule in real life after switching of post-TCZ is Rituximab. On the other hand, up to a third of patients return to treatment with TCZ due to failure to switch to the first biologic post-TCZ.
- REAL WORLD DATA FROM A SINGLE CENTER: SURVIVAL RATES OF TNFi AS FIRST AND SECOND LINE TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_4227;
TNFi display good overall survival rates as first line treatment among PsA with inadequate response to cDMARDs. Female gender and peripheral involvement are independent risk factors for early secondary inefficacy to first TNFi.
- Tremfya (guselkumab) / J&J
COMPARISON OF ON-LABEL TREATMENT PERSISTENCE IN REAL-WORLD PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB VERSUS SUBCUTANEOUS TNF INHIBITORS () - May 29, 2024 - Abstract #EULAR2024EULAR_4174;
Adults with PsA newly initiated on guselkumab or the first observed SC TNFi (i.e., adalimumab, certolizumab pegol, etanercept, or SC golimumab) between 7/14/2020 and 3/31/2022 were selected from the IQVIA TM Health Plan Claims Data. This real-world study assessing treatment persistence in PsA using administrative claims data demonstrated that guselkumab was associated with significantly longer on-label persistence through 12 months versus SC TNFi.
- INFLAMMATORY DISEASES AND RISK OF NEOPLASIA: IS IT THE TREATMENT OR THE DISEASE IN SINE? DATA ON THE MANAGEMENT OF INFLAMMATION IN CASE OF COEXISTENCE WITH MALIGNANCY () - May 29, 2024 - Abstract #EULAR2024EULAR_4000;
It appears that the risk of relapse of inflammation in patients receiving bDMARDs is high. Although these agents appear to be safe in patients with a history of cancer (without evidence of tumor activity), additional data is needed to determine the correct timing of restarting the treatment.
- DISEASE FLARES IN PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWING COVID-19 BREAKTHROUGH INFECTION: RESULT FROM COVAD E-SURVEY STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3841;
Although these agents appear to be safe in patients with a history of cancer (without evidence of tumor activity), additional data is needed to determine the correct timing of restarting the treatment. Younger age (odds ratio (OR): 0.98, 95% CI: 0.96
- WHAT IS THE TRUTH? - COMPARISON OF REACTIONS AND ADVERSE EVENTS BETWEEN JAK INHIBITORS AND ANTI-TNFS - REAL LIFE EXPERIENCE () - May 29, 2024 - Abstract #EULAR2024EULAR_3757;
No major cardiovascular events or thrombotic events were found in a great population of patients using JAKs inhibitors in recent two years. Larger studies are required in the Latin American population to confirm these results.
- VIRAL INFECTIONS AMONG PATIENTS RECEIVING BIOLOGICS FOR RHEUMATIC DISEASES () - May 29, 2024 - Abstract #EULAR2024EULAR_3673;
Biological therapies, especially TNF alpha inhibitors, may lead to an increased risk of viral infections. These infections were reported in 6% of our patients.
- Humira (adalimumab) / AbbVie
NON-MEDICAL SWITCH OF BIOLOGIC DRUGS IN PATIENTS WITH RHEUMATIC DISEASE () - May 29, 2024 - Abstract #EULAR2024EULAR_3572;
Patients with SpA were the most affected. Golimumab has the preferred application device.
- Cimzia (certolizumab pegol) / Astellas, UCB
DO HIGH RHEUMATOID FACTOR LEVELS IMPACT RESPONSE TO CERTOLIZUMAB PEGOL IN PATIENTS WITH INADEQUATELY CONTROLLED RHEUMATOID ARTHRITIS? A POST HOC ANALYSIS OF THE PHASE 3B REALISTIC TRIAL () - May 29, 2024 - Abstract #EULAR2024EULAR_3472;
P3
In contrast, pts with RA and high RF levels who were treated with CZP had similar clinical responses to those with low RF levels, indicating that RF does not influence the response to CZP. These data expand previous notions 5 to a TNFi-IR population.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
CIRCULATING ADIPOKINES AND RESPONSE TO TREATMENT IN EARLY RHEUMATOID ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3440;
Baseline adiponectin, leptin, and resistin levels are not associated with the likelihood of achieving CDAI remission over 48 weeks in this large trial of first-line treatments in early RA. Our results underscore the importance of adjusting for confounders when studying the effects of adipokines on RA outcomes, as circulating adipokine levels are highly dependent on other factors, such as BMI and sex.
- FOLLOW-UP DATA ON DRUG-INDUCED LUPUS CASES DURING TNF-ALPHA INHIBITOR TREATMENT () - May 29, 2024 - Abstract #EULAR2024EULAR_3249;
In patients who develop positive ds-DNA during the use of TNF inhibitors and exhibit mild symptoms, close monitoring while continuing the TNF inhibitor appears to be safe. Larger-scale studies are needed to establish a diagnosis, treatment, and follow-up algorithm in this field.
- Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
EFFECTS OF ONE-YEAR ANTI-TNF-? THERAPY ON NATURAL AUTOANTIBODIES IN ASSOCIATION WITH VASCULAR PATHOPHYSIOLOGY IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3007;
Biologic therapy also increased anti-CS and anti-TOPO-F4 levels. The production of nAAbs was variably associated with, among other parameters, CRP, disease activity and vascular pathophysiology suggesting that nAAbs might form a link between arthritis and atherosclerosis.
- Cimzia (certolizumab pegol) / Astellas, UCB
EFFECTIVENESS OF CERTOLIZUMAB ON FEMALE PATIENTS WITH CHRONIC ARTHRITIS ACCORDING TO THE FERTILITY OR MENOPAUSAL AGE. ANALYSIS FROM THE APULIAN BIOPURE REGISTRY () - May 29, 2024 - Abstract #EULAR2024EULAR_3006;
Figure 1. Table 1.
- PATTERNS OF bDMARDs PRESCRIPTION IN SPONDYLOARTHRITIS AFTER FIRST TNFi FAILURE () - May 29, 2024 - Abstract #EULAR2024EULAR_2902;
Since 2017, novel targets have emerged, and IL-17i have showed efficacy in controlling disease activity. In our study, 50% of the patients started the 2 nd line bDMARD before 2017, so, as expected, most patients were TNFi cyclers.
- Cimzia (certolizumab pegol) / Astellas, UCB
EFFICACY OF CERTOLIZUMAB PEGOL IN PREVENTING ANTERIOR UVEITIS FLARES COMPARED WITH STANDARD NON-BIOLOGIC TREATMENT: A MATCHED CONTROL STUDY IN HIGH-RISK PATIENTS WITH AXIAL SPONDYLOARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_2873;
P4
In our study, 50% of the patients started the 2 nd line bDMARD before 2017, so, as expected, most patients were TNFi cyclers. This matched control study supports the benefit of CZP over standard non-biologic treatment in reducing anterior uveitis flares among high-risk patients with axSpA, highlighting its potential as a promising therapeutic option in managing this debilitating ocular manifestation in axSpA.
- Cosentyx (secukinumab) / Novartis, Cimzia (certolizumab pegol) / Astellas, UCB
DRUG SURVIVAL AND PREDICTOR FACTORS OF DISCONTINUATION IN AXIAL SPONDYLOARTHRITIS PATIENTS RECEIVING CERTOLIZUMAB AND SECUKINUMAB () - May 29, 2024 - Abstract #EULAR2024EULAR_2868;
Notably, gender differences in drug discontinuation were observed, with females showing divergent retention patterns for the two drugs. These findings highlight the need for gender-specific considerations in AxSpA treatment strategies.
- || Rekovelle (follitropin delta) / Ferring
Review, Journal: The pregnancy outcomes among women receiving individualized algorithm dosing with follitropin delta: a systematic review of randomized controlled trials. (Pubmed Central) - May 29, 2024
The personalized individualized-based algorithm dosing with follitropin delta is non-inferior to conventional follitropin alfa or follitropin beta. It is as effective in promoting a similar response in women without significant comparable adverse effects.
- || PRIM-DJ2727 / UT Health Science Center, Vowst (fecal microbiota spores, live-brpk) / Seres Therap, Nestle, Rebyota (fecal microbiota, live-jslm) / Ferring
Review, Journal: Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone. (Pubmed Central) - May 27, 2024
It is as effective in promoting a similar response in women without significant comparable adverse effects. PubMed was reviewed on 1 October 2023, for all papers published concerning the current Food and Drug Administration allowance of the use of fecal microbiota transplantation (FMT) and the studies that led to the licensure of RBX2660 (REBYOTA
- || Rebyota (fecal microbiota, live-jslm) / Ferring
Retrospective data, Review, Journal: Efficacy of Fecal Microbiota (REBYOTA) in Recurrent Clostridium difficile Infections: A Systematic Review and Meta-Analysis. (Pubmed Central) - May 27, 2024
Patients who received RBX2660 (REBYOTA) were significantly less likely to have recurrent Clostridium difficile than controls eight weeks after treatment. This effect is seen in both those who got one or two doses of RBX2660 (REBYOTA), although the FDA currently approves one dose.
- | Cervidil (dinoprostone) / Ferring
Retrospective data, Journal: A model to predict delivery time following induction of labor at term with a dinoprostone vaginal insert: a retrospective study. (Pubmed Central) - May 26, 2024
This effect is seen in both those who got one or two doses of RBX2660 (REBYOTA), although the FDA currently approves one dose. Our findings may help obstetricians estimate the DT before placing a dinoprostone insert, which may improve patient management in busy maternity wards and minimize potential risks.
- || Review, Journal: Biologics for Psoriasis. (Pubmed Central) - May 26, 2024
IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-? inhibitors.
- | Retrospective data, Journal, HEOR: Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims Data. (Pubmed Central) - May 24, 2024
inhibitors. Further research should explore reasons leading to treatment discontinuation in order to support treatment choices for patients with moderate-to-severe psoriasis.
- || VE303 / Vedanta Biosci, Vowst (fecal microbiota spores, live-brpk) / Seres Therap, Nestle, Rebyota (fecal microbiota, live-jslm) / Ferring
Review, Journal: A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent Clostridioides difficile Infection. (Pubmed Central) - May 24, 2024
This article will be an in-depth review of five microbiome therapeutic products that are either under investigation or currently commercially available: Rebyota (fecal microbiota, live-jslm, formerly RBX2660), Vowst (fecal microbiota spores, live-brpk, formerly SER109), VE303, CP101, and RBX7455. Included in this review is a comparison of the products' composition and dosage forms, available safety and efficacy data, and investigational status.
- ||||| Rekovelle (follitropin delta) / Ferring
Enrollment closed: ADAPT-1: A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation (clinicaltrials.gov) - May 22, 2024
P3, N=302, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Included in this review is a comparison of the products' composition and dosage forms, available safety and efficacy data, and investigational status. Recruiting --> Active, not recruiting
- ||| Journal, Adverse events, Real-world evidence, Real-world: Neurological disorders following the use of tumor necrosis factor-? inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis. (Pubmed Central) - May 21, 2024
However, there were no signals among neurological AEs for golimumab. Neurological signals were detected for TNFi use, indicating that the risk of neurological AEs requires additional attention in clinical use of TNFis.
- || olamkicept (FE999301) / Ferring
Clinical, P1 data, PK/PD data, Clinical Trial,Phase I, Journal: Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials. (Pubmed Central) - May 21, 2024
Complete target engagement (inhibition of phosphorylation of signal transducer and activator of transcription-3) was achieved in blood around or above olamkicept serum concentrations of 1-5 ?g/mL. Overall, these results suggest that olamkicept is safe and well-tolerated in healthy subjects and patients with CD after single intravenous/SC and multiple intravenous administrations.
- || PK/PD data, Review: Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review. (Pubmed Central) - May 20, 2024
Available information suggests that the anatomical and physiological changes throughout pregnancy may have meaningful effects on the PK of mAbs. For most mAbs (not IFX), modestly higher dosing (per mg) maybe needed during pregnancy to sustain a similar serum exposure compared to pre-pregnancy.
- | Journal: Rheumatoid factor titers, but not Fc fragments, may be strongly associated with drug survival of anti-TNF agents in patients with rheumatoid arthritis. (Pubmed Central) - May 17, 2024
For most mAbs (not IFX), modestly higher dosing (per mg) maybe needed during pregnancy to sustain a similar serum exposure compared to pre-pregnancy. Our results suggest that compared to the Fc fragment, RF titers were the more important risk factor in survival of anti-TNF drugs.
- | Journal: Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (Pubmed Central) - May 15, 2024
Our results suggest that compared to the Fc fragment, RF titers were the more important risk factor in survival of anti-TNF drugs. The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.